Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)

Endocrinology

Volumn 142, Issue 7, 2001, Pages 2776-2788

  McClelland, Richard A ^a   Barrow, Denise ^a   Madden, Tracie Ann ^a   Dutkowski, Carol M ^a   Pamment, Joanna ^a   Knowlden, Janice M ^a   Gee, Julia M W ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG WITHDRAWAL; ESTROGEN RESPONSIVE ELEMENT; GROWTH INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034987631     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.7.8259     Document Type: Article

References (58)

1. Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments
2. Mechanisms of tamoxifen resistance
3. William M. McGuire Memorial Lecture Antiestrogens: Mechanisms of action and resistance in breast cancer
4. ICI 182,780 (Faslodex™) Development of a novel, 'pure' antiestrogen
5. Investigation of a new pure antioestrogen (ICI 182,780) in women with primary breast cancer
6. Pure antioestrogens (ICI 164384 and ICI 182,780) and breast cancer: Is the attainment of complete oestrogen withdrawal worthwhile?
7. Pure antiestrogens: The most important advance in the endocrine therapy of breast cancer since 1896?
8. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes
9. Effects of the pure antioestrogen ICI 182,780 on oestrogen receptor, epidermal growth factor receptor and transforming growth factor receptor alpha protein expression in human breast cancer
10. Antiestrogen ICI164384 reduces cellular oestrogen receptor content by increasing its turnover
11. Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164384 appears to be mediated by impaired receptor dimerization
12. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
13. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer
14. Resistance of human breast cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness
15. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the non-steroidal antiestrogen tamoxifen
16. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
17. Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
18. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy
19. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
20. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinquinazolines
21. New EGFR selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC3 and DU-145
22. Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation
23. Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue
24. Production of monoclonal antibodies to human estrogen receptor (ER) using recombinant ER (RER)
25. ER ID-5 and H222 (ER-ICA) antibodies to human estrogen receptor protein in human breast carcinomas. Results of a multicentric study
26. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples
27. A multi-centre study into the reliability of steroid receptor immunocytochemical quantification
28. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
29. The use of reverse-transcription-polymerase chain reaction (RT-PCR) methodology to detect estrogen-regulated genes in small breast cancer specimens
30. Human epidermal growth factor receptor cDNA sequence and abberant expression of the amplified gene in A431 epidermoid carcinoma cells
31. Lipofection: A highly efficient lipid-mediated DNA-transfection procedure
32. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA) the c-Ha-ras oncoprotein and the c-jun protein
33. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo
34. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen-resistance in sublines of MCF-7 human breast cancer cells
35. Oestrogen receptor mutants and variants in breast cancer
36. Variant human breast tumor estrogen receptor with constitutive transcriptional activity
37. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling
38. Differential expression of oestrogen regulated genes in breast cancer
39. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
40. Differential regulation of gene expression by estrogen in estrogen-growth independent and dependent MCF7 human breast cancer cell sublines
41. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo
42. Proliferation, hormonal responsiveness and estrogen receptor content of MCF7 human breast cancer cells grown in the short term and long term absence of estrogens
43. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells
44. Transition of human breast cancer cells from and oestrogen responsive to unresponsive state
45. Estrogen-mediated suppression of EgfR expression in estrogen responsive breast cancer cells
46. Bimodal regulation of EGF receptor by estrogen in breast cancer cells
47. The role of estrogen in the regulation of EGFR expression
48. Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EgfR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
49. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
50. Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF7 cells transfected with HER2/neu
51. Progression of MCF7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
52. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumours with acquired tamoxifen resistance
53. c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone-resistant phenotype
54. Anti-sense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells
55. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells
56. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
57. Acquired antiestrogen resistance in MCF7 human breast cancer sublines is not accomplished by altered expression of receptors in the erbB-family
58. Human breast cancer cell lines resistant to pure antioestrogens are sensitive to tamoxifen treatment